BrightGene Bio-Medical Technology

Peptide API / biosimilars

688166 · SSE · China

Public Market Listing

688166SSE

SSE primary exchange listing

Live quotes, historical charts, and market capitalization for BrightGene Bio-Medical Technology are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
GLP-1/GIP receptor (dual)Peptide
ObesityType 2 Diabetes
Phase 2
Amylin/calcitonin receptor (dual)Peptide
Obesity

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
February 2027 (1)
BGM0504Phase 2Overweight or Obese Participants Without Diabetes
Est. primary completion 2027-02-28 · NCT07658560 · CT.gov ↗
What to watch
April 2027 (1)
BGM0504Phase 3Type 2 Diabetes (T2DM)
Est. primary completion 2027-04-30 · NCT07064486 · CT.gov ↗
What to watch
August 2027 (1)
BGM1812Phase 2Overweight or Obese Participants Without Diabetes
Est. primary completion 2027-08-01 · NCT07918625 · CT.gov ↗
What to watch
2028 (1)
September 2028 (1)
BGM0504Phase 3Type 2 Diabetes (T2DM)
Est. primary completion 2028-09-30 · NCT07743983 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

12 June 2026Filing acceptedBGM0504NMPA CDE accepts the BGM0504 injection NDA for weight management
CN, NMPA · BrightGene Pharmaceutical (Suzhou) Co., Ltd. (BrightGene subsidiary) · Source ↗
7 May 2026Topline resultBGM0504BGM0504 Phase III topline positive in overweight or obesity
BrightGene Bio-Medical · Source ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3——$24M—report ↗

BrightGene Bio-Medical Technology reported cash and equivalents of $24.38M for Q3 2025.

Figures only: this period's report disclosed no narrative text

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$170M$83M——report ↗
View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY——$56M—report ↗